Katrina S. Pedersen

6.0k total citations
73 papers, 970 citations indexed

About

Katrina S. Pedersen is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Katrina S. Pedersen has authored 73 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 23 papers in Surgery and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Katrina S. Pedersen's work include Colorectal Cancer Treatments and Studies (23 papers), Pancreatic and Hepatic Oncology Research (19 papers) and Colorectal and Anal Carcinomas (17 papers). Katrina S. Pedersen is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Pancreatic and Hepatic Oncology Research (19 papers) and Colorectal and Anal Carcinomas (17 papers). Katrina S. Pedersen collaborates with scholars based in United States, Switzerland and United Kingdom. Katrina S. Pedersen's co-authors include Robert R. McWilliams, Gloria M. Petersen, Michael J. Overman, John Christiansen, Pia Jensen, Jesper V. Olsen, Poul Erik Mortensen, Patrick M. Boland, Andrea Wang‐Gillam and Tanios Bekaii‐Saab and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Katrina S. Pedersen

63 papers receiving 951 citations

Peers

Katrina S. Pedersen
Alessia Mennitto Italy
Akitaka Makiyama Japan
Mustapha Tehfé Canada
D. A. Singh United States
Diana L. Hanna United States
Natsuko Okita Japan
Claudia Maggi Italy
Elena Maccaroni Italy
B. Barón Belgium
Roger Sidhu United States
Alessia Mennitto Italy
Katrina S. Pedersen
Citations per year, relative to Katrina S. Pedersen Katrina S. Pedersen (= 1×) peers Alessia Mennitto

Countries citing papers authored by Katrina S. Pedersen

Since Specialization
Citations

This map shows the geographic impact of Katrina S. Pedersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katrina S. Pedersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katrina S. Pedersen more than expected).

Fields of papers citing papers by Katrina S. Pedersen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katrina S. Pedersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katrina S. Pedersen. The network helps show where Katrina S. Pedersen may publish in the future.

Co-authorship network of co-authors of Katrina S. Pedersen

This figure shows the co-authorship network connecting the top 25 collaborators of Katrina S. Pedersen. A scholar is included among the top collaborators of Katrina S. Pedersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katrina S. Pedersen. Katrina S. Pedersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Grierson, Patrick, Rama Suresh, Andrea Wang‐Gillam, et al.. (2025). Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. Clinical Cancer Research. 31(17). 3644–3651.
3.
Ajani, Jaffer A. & Katrina S. Pedersen. (2024). Management of MSI-H/dMMR Upper and Lower Gastrointestinal Cancers. Journal of the National Comprehensive Cancer Network. 22(Supplement). 1 indexed citations
4.
Grierson, Patrick, Rama Suresh, Benjamin Tan, et al.. (2023). A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Clinical Cancer Research. 29(23). 4733–4739. 7 indexed citations
5.
Grierson, Patrick, Rama Suresh, Benjamin Tan, et al.. (2023). A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy.. Journal of Clinical Oncology. 41(16_suppl). e16263–e16263. 1 indexed citations
6.
Pedersen, Katrina S., et al.. (2023). Plasma-only multiomic minimal residual disease (MRD) testing in 2,000 consecutive patients with colorectal cancer (CRC).. Journal of Clinical Oncology. 41(4_suppl). 28–28. 2 indexed citations
7.
Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719. 19 indexed citations
8.
Grierson, Patrick, Benjamin Tan, Katrina S. Pedersen, et al.. (2022). Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma. The Oncologist. 28(2). e115–e123. 24 indexed citations
9.
İnce, Semra, Malak Itani, Lauren E. Henke, et al.. (2022). FDG-PET/MRI for Nonoperative Management of Rectal Cancer: A Prospective Pilot Study. Tomography. 8(6). 2723–2734. 8 indexed citations
10.
Li, Chen, Ana Ferro, Shivani K. Mhatre, et al.. (2022). Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. SHILAP Revista de lepidopterología. 2(1). 90–90. 13 indexed citations
11.
Weinberg, Benjamin A., et al.. (2022). Immunotherapy for Colorectal Cancer. Hematology/Oncology Clinics of North America. 36(3). 603–626. 1 indexed citations
12.
Pedersen, Katrina S., Nathan R. Foster, Michael J. Overman, et al.. (2021). ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clinical Cancer Research. 27(13). 3641–3648. 38 indexed citations
13.
Jatoi, Aminah, Fang‐Shu Ou, Daniel H. Ahn, et al.. (2021). Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. The Oncologist. 26(7). 610–618. 5 indexed citations
14.
Kim, Hyun, et al.. (2021). Oncology Trainee Perceptions of the Prior Authorization Process: A National Survey. Advances in Radiation Oncology. 7(2). 100861–100861. 8 indexed citations
15.
Raghav, Kanwal, Takayuki Yoshino, Hiroya Taniguchi, et al.. (2021). P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer. Annals of Oncology. 32. S111–S111.
16.
Pedersen, Katrina S., Patrick Grierson, Joel Picus, et al.. (2021). Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study. Investigational New Drugs. 39(5). 1298–1305. 25 indexed citations
17.
Sanjeevaiah, Aravind, Rama Suresh, Rutika Mehta, et al.. (2020). P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial. Annals of Oncology. 31. S132–S132. 1 indexed citations
18.
Grierson, Patrick, Rama Suresh, Kian‐Huat Lim, et al.. (2020). Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma. Journal of Gastrointestinal Oncology. 11(1). 61–67. 5 indexed citations
19.
Bekaii‐Saab, Tanios, Fang‐Shu Ou, Daniel H. Ahn, et al.. (2019). Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. The Lancet Oncology. 20(8). 1070–1082. 181 indexed citations
20.
Kloesel, Benjamin, et al.. (2012). A 64-Year-Old Man With Progressive Dyspnea and Cough Productive of Copious Amounts of Clear Sputum. CHEST Journal. 141(6). 1622–1625. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Akitaka Makiyama Breakdown of academic impact, for papers by Mustapha Tehfé Breakdown of academic impact, for papers by D. A. Singh Breakdown of academic impact, for papers by Diana L. Hanna Breakdown of academic impact, for papers by Natsuko Okita Breakdown of academic impact, for papers by Claudia Maggi Breakdown of academic impact, for papers by Elena Maccaroni Breakdown of academic impact, for papers by B. Barón Breakdown of academic impact, for papers by Roger Sidhu
Rankless by CCL
2026